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Abstract:  Severe and occasionally fatal arrhythmias, commonly presenting as Torsade de Pointes [TdP] have been 
reported with Class III-antiarrhythmics, but also with non-antiarrhythmic drugs. Most cases result from an action on K
+
channels encoded by the HERG gene responsible for the IKr repolarizing current, leading to a long QT and repolarization 
abnormalities. The hydrophobic central cavity of the HERG-K
+ channels, allows a large number of structurally unrelated 
drugs to bind and cause direct channel inhibition. Some examples are dofetilide, quinidine, sotalol, erythromycin, 
grepafloxacin, cisapride, dolasetron, thioridazine, haloperidol, droperidol and pimozide. Other drugs achieve channel 
inhibition indirectly by impairing channel traffic from the endoplasmic reticulum to the cell membrane, decreasing 
channel membrane density (pentamidine, geldalamicin, arsenic trioxide, digoxin, and probucol). Whereas, ketoconazole, 
fluoxetine and norfluoxetine induce both direct channel inhibition and impaired channel trafficking. Congenital long QT 
syndrome, subclinical ion-channel mutations, subjects and relatives of subjects with previous history of drug-induced long 
QT or TdP, dual drug effects on cardiac repolarization [long QT plus increased QT dispersion], increased transmural 
dispersion of repolarization and T wave abnormalities, use of high doses, metabolism inhibitors and/or combinations of 
QT prolonging drugs, hypokalemia, structural cardiac disease, sympathomimetics, bradycardia, women and older age, 
have been shown to increase the risk for developing drug-induced TdP. Because most of these reactions are preventable, 
careful evaluation of risk factors and increased knowledge of drugs use associated with repolarization abnormalities is 
strongly recommended. Future genetic testing and development of practical and simple provocation tests are in route to 
prevent iatrogenic TdP.  
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INTRODUCTION 
  The potentially dangerous proarrhythmic effects of drugs 
have been recognized since the days when digitalis and 
quinidine toxicities were described [1]. Subsequently, with 
widespread use of newer antiarrhythmic drugs, in particular 
agents with class III activity, many cases of drug-induced 
arrhythmia were documented [1]. However, not until 
recently we have become aware that many non-antiarrhy-
thmic drugs have proarrhythmic activities and in fact have 
been associated with severe and occasionally fatal 
arrhythmias, commonly presenting as Torsade de Pointes 
(TdP) [1-6].  
  Several agents of distinct pharmacological classes have 
been removed from the market or their use limited because 
of deaths related to ventricular arrhythmias. Among these 
agents are antibiotics (Grepafloxazin - Raxar®), prokinetics 
(Cisapride - Propulsid®), antihistaminics (Terfenadine - 
Seldane®; Astemizole - Hismanal®), and antipsychotics 
(Sertindole - Serlect
®) [1, 2]. Cisapride, for example, is 
available only through a limited-access program and its use 
is indicated for patients who have failed other therapies, have 
a normal ECG and in consultation with a specialist. 
Warnings have also been issued for droperidol because of its 
propensity to induce QT prolongation and fatal arrhythmia 
[7].  
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  TdP was first described by Dessertenne [8, 9] as a “poly-
morphic ventricular tachycardia characterized by an electro-
cardiographic pattern of continuously changing morphology 
of QRS complexes that seem to twist around the imaginary 
baseline”. TdP may manifest as palpitations, syncope, 
seizure-like activity, cardiac arrest requiring resuscitation 
and defibrillation, and/or as sudden cardiac death. It is thus 
apparent, that although TdP may present as a short-lived and 
self-limited arrhythmia, it may also lead to fatal events [1-5]. 
  Information about the occurrence of TdP in the general 
population is unknown. Although TdP is reported to occur in 
4 out of 100,000 individuals per year, a higher rate would be 
expected in predisposed patient groups [10].  
  TdP is commonly associated with acquired or hereditary 
forms of prolonged QT interval (long QT syndrome, LQTS). 
TdP often starts after the T wave of a markedly prolonged 
QT interval that followed a cycle that had been prolonged, 
usually by a post-ectopic pause. Among the conditions, drug-
induced long QT is by far the most common, and hence, 
preventable. Recent findings suggest that many of the 
acquired forms of TdP develop in individuals who harbor 
subclinical congenital abnormalities. In addition to drugs, 
other predisposing factors for prolonging the QT interval and 
inducing TdP are electrolyte abnormalities and structural 
cardiac disorders. Coexistence of several of the predisposing 
factors in a patient increases the likelihood of developing 
long QT and TdP. Although the duration of the QT interval 
was considered as the best clinical marker for the risk of TdP 
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inhomogeneity) and T wave abnormalities have also been 
associated with increased for TdP [5, 11, 12] (Table 1). 
Table 1.  Factors Associated with Increased Risk of Develop-
ing Drug-Induced Excessive QT Prolongation and/or 
TdP
1. EEG changes [congenital or acquired]: 
a. Long QT interval [20-22, 33-35] 
b. Increased QT dispersion [12, 23-25, 98] 
c. Increased interval from peak to end of T wave [26,99] 
d. T wave alternans [26] 
e. T-U waves [26] 
2. Action Potential 
a. Prolonged [1-5] 
b. Prolonged with triangular shape [67] 
3. Electrolyte abnormalities 
a. Hypokalemia [46-48] 
b. Hypomagnesemia [101] 
4. Women [5,15,95,96] 
5. Older age [97] 
6. HIV [32] 
7. Systolic dysfunction [102] 
8. Previous history of drug induced long QT or TdP [52] 
9. Relatives of subjects with a history of drug-induced long QT [99] 
MECHANISMS OF LONG QT, REPOLARIZATION 
ABNORMALITIES AND TDP 
  The width of the ventricular action potential determines 
the duration of the QT interval on the ECG. In contrast with 
QRS interval, the duration of the QT interval varies from 
beat to beat, shows circadian variation and is affected by 
changes in the heart rate and autonomic tone. The faster the 
heart rate the shorter the QT interval, consequently, a rate 
corrected QT [QTc] is commonly employed [13, 14]. QTc 
values greater than 450 msec for men and 470 msec for 
women are usually considered as abnormally prolonged 
intervals [15]. Recent findings suggest that QT interval 
variation in the general population is largely heritable [16].  
  Ventricular repolarization is mainly due to outward K
+
currents. Two main delayed rectifying currents operate to 
achieve repolarization, a rapid [IKr] and a slow [IKs] 
current. When these currents are reduced, repolarization is 
prolonged, the ventricular action potentials broaden and the 
duration of the QT interval increases. When the period of 
repolarization is prolonged, depolarizing currents may ensue, 
which when repeated and of sufficient magnitude, may 
trigger a ventricular arrhythmia. Both early and late depolari-
zing currents have been described. TdP is classically asso-
ciated with early-afterdepolarizations, which are depolari-
zing currents occurring early during the period of repolari-
zation [17-19], due mostly to inward calcium currents. 
During delayed repolarization, inactive L-type calcium chan-
nels may become active, leading to inward depolarizing 
calcium currents [19]. Therefore, conditions or treatments 
that increase the number of L-type calcium channels in 
cardiac fiber membranes, such as sympathetic stimulation or 
administration of beta-receptor agonists, may facilitate the 
induction of TdP in the presence of delayed repolarization. 
Clinically, the early depolarizations correlate well with the 
presence of T wave humps, T-U waves or bifid T waves that 
often precede the development of TdP [18]. 
  Interference with the IKr current leading to prolonged 
repolarization and long QT is the most common mechanism 
of congenital and drug-induced triggered arrhythmia [20-22]. 
The IKr repolarizing current is conducted through K
+
channels that are coded by the human human-ether-a-go-go-
related gene (HERG).In addition to prolonged repolarization 
[i.e., long QT], the interlead variation of QT duration in a 
surface electrocardiogram also known as QT dispersion or 
variability predicts risk of TdP [12, 23]. QT dispersion is 
indicative of spatial heterogeneity of repolarization times in 
the ventricular muscle. Differences in the time course of 
repolarization of the cell layers that make up the ventricular 
myocardium give rise to transmural voltage gradients and a 
dispersion of repolarization. QT dispersion is commonly 
calculated from the difference between the maximum and the 
minimum QTc in any thoracic lead. Values greater than 80 
msec are considered abnormally prolonged [24]. In the 
presence of a prolonged QT interval, repolarization inhomo-
geneity increases the risk of TdP [5]. Bradycardia is 
associated with increased risk for developing TdP due to a 
combination of prolonged QT and increased transmural 
dispersion of repolarization. Further, agents that prolong the 
QT interval but fail to increase the transmural dispersion of 
repolarization may not induce TdP [25]. Consequently, EKG 
assessments of increased risk of TdP should include: QT 
interval duration, beat-to-beat QT variability (QT dis-
persion), interval from peak to the end of the T wave, 
presence T-wave alternans [change in amplitude or polarity 
of T wave on alternating beats] and “T-U waves” [26, 27] 
(Table 1).  
  The significance of repolarization abnormalities on 
outcomes was recently assessed. Long QT (>440msec) 
associated with high -natriuretic peptide levels, were found 
to be an independent predictor of mortality in advanced CHF 
and in heart transplant patients [28, 29]. Additionally, QT 
duration and dispersion abnormalities were found to be 
significant predictors of cardiac mortality in the general 
population as well as in diabetics [30, 31] (Table 1).
GENETIC BASIS FOR IATROGENIC-LONG QT AND 
TDP 
  In the absence of structural disease (ischemic heart 
disease, congestive heart failure, cardiomyopathies), marked 
bradycardia, electrolyte abnormalities such as low potassium 
and low magnesium, subarachnoid hemorrhage, human 
immunodeficiency virus disease [32], or drug therapy, the 
presence of an abnormally prolonged QTc interval is 
suggestive of congenital long QT [33-35]. Genetic predis-
position and acquired risk actors interact in an individual to 
produce an increased risk of TdP arrhythmia. The concept of 
repolarization reserve has been employed to account for 
individual differences in the susceptibility to develop TdP 
with drugs or conditions known to affect K
+currents. 
  Mutations in the genes coding for transmembrane ion-
channel proteins cause most cases of congenital long QT 
syndrome [36]. Seven different genes and over 400 
mutations have been identified so far [36]. Mutations in 
potassium channel genes (KCNQ1, KCNH2, KCNE1, 
KCNE2, KCNJ2), as well as in sodium (SCN5A) and 
calcium channel genes (CACNA1C) have been described 
[36-38]. However, 90% of all cases have defects in genes 
coding for ion channels involved in repolarizing K
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the IKs ion channels (LQTS1, chromosome 11) of this ion 
channels (LQTS2, chromosome 7). HERG alpha-subunits 
and MiRP1 (MinK-related peptide beta-subunits-1) consti-
tute the native human IKr. Mutations of HERG and MiRP1 
decrease the repolarizing current, delay ventricular repo-
larization and prolong the QT interval [21, 37, 38]. Few 
patients have defects in genes coding for sodium channels 
(LQTS3, chromosome 5). Patients with the congenital forms 
of the LQTS may present with frequent episodes of 
arrhythmias and syncope associated with TdP [1]. In some, 
the arrhythmias are triggered by exercise, whereas in others 
arrhythmias are independent of physical activity presenting 
at night and at rest. Arrhythmias triggered by auditory 
stimuli, low serum potassium and clarithromycin have also 
been reported. In the near future, the management of LQTS 
may be greatly facilitated by recognition of the type of 
mutation present in an individual. For example, LQTS 
subjects with a MiRP1 mutation in the potassium channel 
should avoid clarithromycin and macrolide antibiotics [39].  
  In addition to mutations known to affect the function of 
the ion channels (loss of function mutations), mutations 
leading to a reduced number of functional channels or in the 
rate of incorporation of channels into the cell membrane may 
also lead to severe and fatal arrhythmias [40]. Assembled 
channels are normally transferred from the endoplasmic 
reticulum into the cell membrane. Channel mis-processing 
and/or abnormal channel trafficking may affect ion currents 
[40]. For example, subjects with LQTS3 have a mutation on 
the SCN5A cardiac sodium channel. Such a mutation delays 
the incorporation of the sodium channels into the cell 
membrane, leading to late depolarizing currents, which may 
trigger an arrhythmia. Similarly, subjects with LQTS2 
harboring HERG N470D and HERG R752W mutations have 
impaired trafficking of potassium channels from the 
endoplasmic reticulum to the cell surface, reducing the 
density of channels in the cell surface, and thus presenting as 
a long QT syndrome [41-44]. Because the mutated channels 
are retained in the endoplasmic reticulum, strategies are 
being developed to restore normal trafficking. Several 
chemical chaperones and some HERG- K
+ channel blockers, 
such as astemizole and cisapride, have been shown to rescue 
HERG K
+ channels under in vitro conditions [43]. Unfor-
tunately, the clinical usefulness of aztemizole and cisapride 
to correct defective channel trafficking is limited by their 
stronger potency as channel blockers than as channel 
trafficking stabilizers. Selective HERG K
+ channel rescue 
agents lacking ion channel blocking activity are being 
currently developed [45]. 
SERUM POTASSIUM, LONG QT AND TDP 
  Low levels of serum K
+ are associated with increased 
risk for TdP (Table 1). Unlike most K
+ currents, the 
magnitude of the IKr current is reduced by low extracellular 
K
+ concentrations, further prolonging repolarization [46]. 
This probably explains the marked QT prolongation and the 
induction of TdP observed in patients receiving an IKr 
antagonist in the presence of low serum K
+ [47]. As for 
drugs that inhibit the IKr currents, the arrhythmogenic effect 
of low serum K
+ is enhanced in the presence of bradycardia 
[35, 46]. Reductions in serum K
+ are also known to increase 
the incidence of arrhythmia in subjects with a LQTS. Choi 
and colleagues [48] studied the effects of a K
+ infusion in 
healthy volunteers and in CHF patients during a challenge 
with quinidine. K
+ administration (0.5 mEq/kg, maximum 40 
mEq, in 0.9% saline in one-hour infusion) reduced the 
duration and dispersion of the QTc interval, and reversed the 
morphological QT abnormalities, including U waves and 
bifid T waves in both groups of subjects. These beneficial 
ECG changes were observed with increases in serum K
+ of 
0.4 to 0.7 mEq/lt, and with baseline serum K
+ within normal 
levels. Increasing the serum K
+ from low normal (4.1 
mEq/lt) to high normal (4.8 mEq/lt) reduced QTc duration 
by approximately 100 msec [48]. Increases in serum K
+ to 
levels above 4.0 mEq/lt have also been reported to correct 
the ECG abnormalities in patients with congenital forms of 
the long QT syndrome. ECG abnormalities of subjects with 
LQTS2 due to mutations in the HERG gene were corrected 
by K
+ treatment [49]. It is proposed that the conventional 
lower limit for serum K
+ should be raised in patients with 
LQTS, either congenital or acquired, as well as in subjects 
scheduled to receive treatment with drugs known to prolong 
the QT interval.  
MECHANISMS OF DRUG-INDUCED REPOLARIZA-
TION ABNORMALITIES AND INCREASED RISK 
FOR TDP 
  As with congenital forms of long QT syndrome, most 
cases of drug-induced long QT and TdP result from an action 
of the drugs on the ion channel proteins encoded by the 
HERG gene that is responsible for the IKr repolarizing 
current. Drug-induced QT prolongation is most commonly 
achieved by direct channel blockade. Interestingly, contrary 
to most drug-receptor interactions, binding to the HERG K
+
channels seems to be quite unspecific. A large number of 
structurally unrelated drugs exert direct blockade of the 
HERG K
+ channels. Such unspecific drug-channel interac-
tion seems to result from the large number of aromatic 
residues present in the K
+ channel compared with other ion-
channels [44]. It has been proposed that the hydrophobic 
central cavity of the HERG K
+ channels may stabilize the 
binding of drugs to the channel protein leading to IKr 
inhibition [44].  
  In addition to drug-induced direct HERG K
+ channel 
blockade, some agents (Table 2) induce repolarization abnor-
malities by inhibiting channel trafficking, reducing the 
incorporation of K
+ channels into the cell membrane [20-22, 
34]. Drugs such as ketoconazole, fluoxetine, and norfluo-
xetine induce QT-prolongation via a dual mechanism, i.e., 
direct channel blockade and inhibition of cellular channel 
trafficking (Table 2). It is expected that the list of drugs with 
effects on HERG K
+ channel trafficking will increase, as 
more agents are tested for such an action.  
  Although many drugs inhibit the IKr, fortunately only 
very few patients develop TdP when treated with QT- 
prolonging drugs [5]. The low incidence and often-
unpredictable emergence of TdP may result from individual 
differences in pharmacokinetics and/or pharmacogenomics. 
In this regard, it has been proposed that subjects susceptible 
to drug-induced TdP (i.e, low repolarization reserve) may 
have mutations in the HERG K
+ channel, which would 
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50]. Up to 20% of people developing drug-induced TdP were 
found to have a low repolarization reserve due to subclinical 
ion-channel mutations [51]. In addition to genetic factors, 
drugs may exert multiple actions on cardiac repolarization. 
The increased risk for developing TdP with high doses of 
sotalol will result from a dual drug effect on cardiac 
repolarization, i.e., prolonged repolarization and increased 
repolarization heterogeneity. Conversely, concomitant drug 
actions on ion channels (i.e., calcium channel blockade) and 
receptors (beta receptor antagonism) may override the risk of 
TdP associated with IKr inhibition. Amiodarone and 
verapamil exemplify this situation. These findings also 
indicate that a normal QT at baseline does not preclude 
excessive QT prolongation and even development of TdP 
when exposed to a QT-prolonging drug [52]. Importantly, a 
previous history of drug-induced TdP should preclude the 
use of a QT prolonging drug. 
DRUG CLASSES ASSOCIATED WITH LONG QT 
AND TDP 
  Antiarrhythmic drugs with class III activity (IKr 
blockade) are expected to increased risk for developing TdP 
[34, 53] (Table 3). These agents act as antiarrhythmics by 
inhibiting outward K
+ current, delaying repolarization, pro-
longing the QT interval and increasing refractoriness. Other 
antiarrhythmics with IKr blocking properties, such as class 
Ia drugs, bepridil and sotalol also prolong the QT interval. 
Quinidine, dofetilide and ibutilide, are all associated with 
TdP and are potent blockers of the IKr channel; thus, for 
these three agents there is a strong association between these 
two variables [46]. Quinidine, not only prolongs the duration 
of QT interval but also increases the transmural dispersion of 
repolarization at slow rather than at faster heart rates. 
Verapamil, on the other hand, is a drug not associated with 
TdP, but it also blocks IKr currents. However, verapamil 
blocks L-type calcium channels and additionally decreases 
transmural dispersion of repolarization; the combi-nation of 
both factors may account for the low incidence of TdP 
associated with its use [54].  
Table  3. Antiarrhythmic Drugs Associated with QT 
Prolongation and Increased Risk for Developing 
TdP










  An interesting example of class III drugs is sotalol; which 
has been associated with TdP. Sotalol is composed on a 
racemic mixture of D- and L-sotalol. D-sotalol inhibits the 
IKr and prolongs the QT interval. L-sotalol, on the other 
hand, is a beta-blocker. The racemic mixture has been 
reported to be less arrhythmogenic than the D-sotalol. The 
SWORD trial reported an increased mortality when D-
sotalol was employed in patients with left ventricular 
dysfunction after recent or remote myocardial infarction 
[55]. The lesser effect of the racemic mixture is most likely 
due to the beta-blocking properties of L-sotalol. Sotalol-
induced recurrent TdP has been observed in patients with 
end-stage renal disease, which may result from very high 
plasma levels of sotalol, since the drug is not adequately 
eliminated by renal dialysis [56]. At high concentrations, 
Table 2.  Mechanisms of Drug-Induced HERG-K
+ Channel Inhibition, QT Interval Prolongation and Increased Risk for TdP 
Drugs  Direct Inhibition of HERG K
+ Channel  Inhibition of HERG K
+ Channel Trafficking 
Phenothiazines +  ? 
Pentamidine -  + 
Geldalamicin -  + 
Arsenic Trioxide  -  + 
Fluoxetine, Norfluoxetine  +  + 
Ketoconazole +  + 
Digitoxin, Ouabain, Digoxin  -  + 
Sparfluoxacin, Ciprofloxacin, Ofloxacin   +  - 
Amsacrin +  - 
Probucol -  + 
Cisapride +   
Drug-induced HERG-K
+ channel inhibition can be achieved either by direct inhibition of potassium channels and/or by reducing the number of channels on the 
cell membrane. The later is achieved by inhibiting HERG-channel trafficking from the endoplasmic reticulum to the cell membrane. Data on drug-induced 
inhibition of channel trafficking is not available for all drugs. Therefore, the table depicts available data for agents that have been tested both for direct HERG-
channel blockade and for interference with channel trafficking [Refs. 77,103-107]. 170 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Luigi X. Cubeddu
sotalol not only prolongs the QT interval but in addition it 
increases beat-to-beat QT interval variability (repolarization 
heterogeneity), increasing the likelihood of developing TdP 
[57].  
  Amiodarone exerts inhibitory effects on the IKr and the 
IKs currents, prolonging repolarization and the QT interval 
[58]. Despite the bradycardia and the large QT prolongation 
associated with chronic amiodarone therapy, TdP and other 
drug-induced tachyarryhthmias are unusual. Amiodarone 
reduces both heterogeneity of repolarization across cell type 
within myocardium (epi, endo and mid-myocardial cells) and 
QT variability [57]. These effects may account for the lower 
than expected incidence of TdP observed with the drug. 
Additionally, amiodarone exerts alpha and beta blocking 
properties and calcium channel blocking activity, as well as 
multiple antiarrhythmic activities, which may also lower the 
risk of TdP [46, 59]. As with most agents that prolong QT, 
TdP associated with amiodarone treatment has been shown 
to be higher in women than in men.  
  Cardiac glycosides are also potent inhibitors of HERG 
expression at the cell surface, reducing IKr currents, and 
prolonging repolarization and the QT interval. Digitoxin, 
ouabain, and digoxin appear to inhibit IKr by reducing the 
density of HERG-dependent potassium channels in the cell 
membrane. The reduced number of potassium channels in 
the cell membrane results from abnormal channel trafficking 
due to inhibition of channel exit from the endoplasmic 
reticulum [60] (Table 2). 
  The protective effects of a rapid rhythm on TdP are well 
documented. Dofetilide a Class III antiarrhythmic induced 
more QT prolongation after rhythm conversion than during 
rapid-rate atrial fibrillation. Cardioversion of atrial fibril-
lation is known to increase the risk of long QT; whereas 
persistent atrial fibrillation has a protective effect for drug-
induced long QT [5]. Additionally, slower heart rates are 
known to increase risk of TdP by QT prolonging drugs, 
some forms of congenital LQTS and hypokalemia. Similarly, 
autonomic block was shown to increase ibutilide-induced 
QT prolongation [61].  
USE OF QT-PROLONGING DRUGS FOR THE 
TREATMENT OF THE SHORT QT SYNDROME 
  Short QT syndrome is a new genetic disorder associated 
with a high rate of familial sudden death [62, 63]. Several 
mutations in genes encoding for cardiac ion channels 
(KCNH2, KCNQ1, and KCNJ2) have been identified to 
cause the short QT syndrome. These mutations lead to an 
increase in the IK currents (IKr, IKs, and IK1), which in turn 
shorten the action potential and the QT interval (<335 ms 
after correction for heart rate at rates <80 beats/min). 
Although an implantable cardioverter defibrillator is often 
the therapy of choice, pharmacological treatment with QT 
prolonging drugs has also been attempted. In a study of 
patients carrying a mutation in the IKr-coding gene KCNH2 
(HERG), quinidine was found more effective than sotalol 
and ibutilide in prolonging the QT interval and normalizing 
the effective refractory periods [62]. The superiority of 
quinidine over Class IC and Class III drugs was confirmed in 
another study [63], where hydroquinidine was found to 
prolong the QT interval from 263 +/- 12 ms to 362 +/- 25 
ms, and to prevent the likelihood of ventricular fibrillation. 
Therefore, drugs known to prolong the QT interval, 
quinidine in particular, can be effective in the treatment of 
short QT interval syndrome. 
NON-ANTIARRHYTHMIC DRUGS ASSOCIATED 
WITH INCREASED RISK OF TDP 
  Although for the class III antiarrhythmics prolonged 
cardiac repolarization is a desired effect, for other agents the 
blockade of repolarization is an unwanted side effect   
(Table 4). The use non-antiarrhythmic QT-prolonging drugs 
increases by 2-fold the risk of cardiac arrest in hospitalized 
patients with several underlying diseases [64]. Such a risk 
was more pronounced in patients receiving more than one 
daily dose of the drug, more than one QT-prolonging drug, 
and drugs that interfere with the metabolism or elimination 
of the QT prolonging agent [64]. For QT prolonging orally 
administered drugs TdP developed within 3 days in only 
18% of cases, between 3 and 30 days in 42% of cases, and 
after 30 days of treatment initiation in 40% of cases [65]. 
TdP associated with intravenous drug administration 
generally occurred at the time of peak plasma levels [65].  
  For many drugs, QT prolongation is described in the 
FDA-approved labeling as a known drug action, and for 
others, the FAD-approved labeling includes cases or a risk of 
TdP. Such information may be accessed at http://www. 
Torsades.org. [6] (Table 4).  
  Antibiotics are among the non-antiarrhythmic therapeutic 
agents known to prolong the QT interval and to be associated 
with TdP. Macrolide antibiotics such as erythromycin, 
clarithromycin and azythromycin have reported to prolong 
the QT interval. However, greater risk of TdP has been 
observed erythromycin and clarithromycin, in particular at 
high doses, and during intravenous administration. Little to 
no risk to TdP has been reported with azythromycin despite 
QT prolongation. Differences in arrhythmogenesis may arise 
from differences in drug-induced changes in the morphology 
of the ventricular action potentials; with a more triangular 
morphology observed with erythromycin and clarythro-
mycin, and a more rectangular morphology with azythro-
mycin (see [67] for details) (Table 1). In addition, to their 
direct effect on the QT interval erythromycin and 
clarithromycin exert inhibitory effects on drug metabolism 
by inhibiting Cyt P450 3A4. Macrolides should be avoided 
in patients taking pimozide or drugs known to prolong the 
QT interval (.e., class Ia, and III antiarrhythmics), and in 
subjects with underlying cardiac disease. High doses of 
macrolides should be avoided, and it has been recommended 
that serum K
+ abnormalities be corrected prior to its use, 
particularly in patients with increased risk for TdP [66]. 
  Antibiotics of the fluoroquinolone class may induce QT 
prolongation and increase the risk of arrhythmia [68-70]. 
The inhibitory potency of fluoroquinolones to inhibit HERG 
K
+ channels was assessed in vitro employing patch-clamp 
electrophysiology techniques. All fluoroquinolone tested 
inhibited the channel, but with widely differing potencies. 
Sparfloxacin was the most potent compound, followed by 
grepafloxacin > moxifloxacin > gatifloxacin > levofloxacin 
> ciprofloxacin > ofloxacin. In the cases of levofloxacin, 
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to occur at concentrations much greater than those observed 
clinically. Sparfloxacin was not only the most potent in inhi-
biting Ikr, but in addition it increased the instability of repo-
larization [71]. Sparfloxacin, gatifluoxazine and moxi-
floxacin should be avoided in patients with risk factors for 
QT prolongation, and the recommended dose should not be 
exceeded. In general, use of any fluoroquinolone should be 
avoided in subjects with LQTS, subjects treated with class Ia 
and III antiarrhythmics or with any other agent known to 
prolong the QT interval [72]. Similarly, fluoroquinolones 
should be administered with caution and under ECG 
monitoring in cardiac disease (ischemic heart disease, CHF, 
bradycardia and rhythm disturbances) and serum K
+ abnor-
malities should be corrected prior to administering fluoro-
quinolones [66, 68, 73]. 
  Pentamidine, an antiprotozoal agent used in the treatment 
of trypanosomiasis, lehismaniasis and Pneumocistis carinii
infections, is known to induce marked QT prolongation and 
arrhythmia [74]. Eisenhauer and colleagues [75] reported 
that in HIV patients with no apparent risk for QT pro-
longation a 1-hr infusion of pentamidine (4 mg/kg/d) 
prolonged the QTc interval by more than 120 msec in 5 of 14 
subjects. Three of the five subjects developed TdP, one of 
whom died. Recent findings suggest that pentamidine-
induced QT prolongation results from inhibition of channel 
trafficking and reduction in membrane channel density, 
rather than to direct channel blockade [76]. Geldalamicin, a 
benzoquinoid antibiotic, has also been shown to inhibit IKr 
currents by reducing trafficking of channels to the cell 
membrane [45]. 
  Several other drugs have been reported to prolong the QT 
interval and to increase the risk of TdP. Cisapride, felbamate, 
forcarnet, tacrolimus, probucol, indapamide, moexipril and 
tizanidine, arsenic trioxide, methadone, octreotide, dola-
setron and halofantrine, are among them [77]. Interestingly, 
the use of serotonin agonists of the tryptan class (sumatri-
ptan, naratriptan and zolmitriptan) has also been associated 
with increased risk for TdP. Strong inhibition of IKr has 
been observed with cisapride and terfenadine. Among the 
antihistaminics, loratadine, terfena-dine and astemizole have 
been shown to block IKr; however, loratadine has little to no 
effect on the QT interval [78]. The later results from the 300-
fold lesser potency of loratadine than of terfenadine and 
astemizole, in blocking the HERG K
+ channels. Ranolazine 
has been shown to induce a modest increase of the QT 
interval, but apparently not associated with increase risk of 
TdP [79]. 
  Domperidone, a dopamine (D2) receptor antagonist with 
prokinetic activity, has been shown to prolong the QT 
interval [80]. Its use was shown to increase the relative risk 
of sudden cardiac death of 3.8 fold [81], and the intravenous 
formulation was withdrawn from the market due to cardiac 
arrhythmias. Domperidone is metabolized by CYP3A4 and 
marked increases in its plasma levels, long QT intervals and 
arrhythmia have been reported when given combined with 
Table 4.  Some Non-Antiarrhythmic Drugs that have been Reported to either Prolong the QT Interval and/or to Increase the Risk 
for Developing TdP 
Drug Class  Chemical Class  Drugs 
Antibiotics  Macrolides  Eryhthomycin, Claritromycin, Telithromycin 
 Fluoroquinolones  Sparfloxacin, Gemifluxacine, Grepafloxacin, Moxifloxacin, Gatifloxacin, 
Levofloxacin 
 Benzoquinoid  Geldamicin 
Antiprotozoals   Pentamidine,  Chloroquine,Halofantrine 
Antifungals   Ketoconazole, Itraconazole, Fluconazole, Miconazole, Posaconazole, 
Voriconazole 
Antineoplastic    Arsenic trioxide, Anthracyclines, Sunitinib 
Prokinetics    Cisapride, Domperidone, Erythromycin, 
5HT3-recptor antagonists    Dolasetron, Granisetron, Ondansetron 
Antihistaminics   Terfenadine, Astemizole 
5-HT1D agonists    Sumatriptan, Naratriptan, Zolmitriptan 
Antipsychotics  Phenothiazines  Thioridazine, Mesoridazine, Chlorpromazine 
 Butyrophenones  Haloperidol,  Droperidol 
  Atypical Neuroleptics  Sertindole, Pimozide, Clozapine, Quetiapine, Risperidone 
Antidepressants  Tricyclic antidepressants  Desipramine, Imipramine, Doxepin. 
Selective Serotonin Uptake 
Inhibitors 
Paroxetine, Sertraline, Doxepin, Venlafaxine, Fluoxetine, Norfluoxetine, 
Fluvoxamine 
Opiods   Levomethadyl,  Methadone. 
Drugs with cardiac and vascular 
effects 
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ketoconazole [82]. Interestingly, although structurally unre-
lated, most prokinetic agents (cisapride, domperidone and 
erythromycin) prolong the QT interval and its use is 
associated with arrhythmogenesis.  
  Drugs used for the treatment of psychosis also share 
arrhythmogenic potential related to repolarization abnor-
malities and QT prolongation. Sudden unexpected death has 
been reported to be nearly twice as frequent in populations 
treated with antipsychotics [83, 84]. Chlorpromazine, thiori-
dazine, mesoridazine, risperidone, zisapridone, haloperidol, 
droperidol, sertindole, quetiapine and pimozide are some of 
the agents associated with prolongation of the QT interval. 
Of the phenothiazines tested, thioridazine was the most 
potent and chlorpromazine the least potent in blocking 
HERG K
+ channels [85]. TdP associated with intravenous 
haloperidol administration is commonly observed within 15 
to 220 min of drug administration [86]. Pimozide, sertindole, 
haloperidol and droperidol have been documented to cause 
TdP and sudden death. However, highest risk seems 
associated with thioridazine and droperidol use [79, 83]. Of 
the antipsychotics, butyrophenones and diphenylbutylpiperi-
dines were reported more potent than the dibenzoxazepines 
as HERG K
+-blocking agents; substituted benzamides 
exhibited the lowest blocking activity [87]. In addition to 
antipsychotics, drugs with antidepressant properties may also 
prolong the QT interval; among them: desipramine, 
imipramine, doxepin, fluvoxamine, fluoxetine, paroxetine, 
sertraline, doxepin and venlafaxine [87, 88]. Both fluoxetine 
and its metabolite, norfluoxetine, have been shown to 
directly inhibit the potassium channels and in addition, 
disrupt channel protein trafficking reducing the number of 
channels in the cell membrane [89] (Table 2).  
  Arsenic trioxide has increasingly been used in the 
treatment of acute promyelocytic leukemia. Arsenic trioxide 
is commonly administered daily as a 2-hour infusion of 0.15 
mg/kg in patients with relapsed or refractory acute pro-
myelocytic leukemia. Such a treatment is known to prolong 
the QT interval, and is frequently associated with nonsus-
tained ventricular tachycardia, requiring additional antiarrhy-
thmic therapy [90]. Therefore, patients treated with arsenic 
trioxide should be monitored for prolonged QT intervals, 
presence of T-U wave alternats and ventricular arrhythmia 
[26]. Arsenic trioxide prolongs the QT interval by inhibiting 
the channel trafficking from the endoplasmic reticulum to 
the cell membrane. The compound seems not to directly 
block the potassium channels [91] (Table 2).  
  Anthracyclines have been shown to be associated with 
TdP and to increase the sensitivity of IKr-blocking drugs to 
induce an arrhythmia; the later may be observed soon after 
initiation of anthracyline treatment. It has been proposed that 
anthracyclines reduce the repolarization reserve increasing 
the likelihood of developing life-threatening proarrhythmia 
[92]. 
  In addition to drugs with significant effects to the QT 
interval, the azole group of antifungals, ketoconazole, itraco-
nazole, fluconazole, miconazole, posaconazole and vorico-
nazole has been reported to cause important interactions with 
agents known to prolong the QT [93]. The azoles per se have 
inhibitory effects on the IKr, but in addition, and in 
particular, ketoconazole, miconazole and itraconazole, are 
known to interfere with the metabolism of many other 
compounds by inhibiting cytochrome P450-3A4. Therefore, 
when combined with QT-prolonging drugs that are 
metabolized by this cytochrome system, large increases in 
plasma levels may occur. In fact, most of the deaths related 
to treatment with cisapride, astemizole, quinidine and 
terfenadine may have resulted from concomitant adminis-
tration with azole compounds [90]. Thus, administration of 
two QT-prolonging drugs together with high plasma levels 
of a QT-prolonging drug are likely to increase the risk of 
TdP. Recent studies demonstrated that ketoconazole pro-
longed the QT not only through direct blockade of the IKr, 
but also by reducing the density (number of) of HERG 
potassium channels in the cell membrane. The channel 
trafficking from the endoplasmic reticulum to the cell 
membrane is inhibited by ketoconazole. Therefore, and 
similarly to fluoxetine and norfluoxetine, ketoconazole-
induced LQTS may be achieved by a combination of two 
effects; namely, via a direct inhibition of the potassium 
channel and by disrupting HERG protein trafficking [94] 
(Table 2). 
  Beta-adrenergic receptor stimulation induced either by 
increased sympathetic stimulation, albuterol, terbutaline, 
salmeterol, isoproterenol, ephedrine, pseudoephedrine, phe-
nylephrine, or phenylpropanolamine, increases (upregulates) 
the number of L-type calcium channels in cardiac fibers, 
facilitating the development of early afterdepolarizations in 
the presence of long QT. Therefore, in the presence of an 
already long QT, and irrespective of its etiology, adminis-
tration of these agents may trigger a ventricular arrhythmia 
[see additional drugs to avoid in patients with long QT, 
under www.torsades.org or www.Qtdrugs.org [6]. 
RISK FACTORS AND PREDICTORS OF DRUG-
INDUCED TDP 
  Women commonly have longer QTc intervals than males 
and have a greater propensity to develop TdP than men [15, 
95, 96] (Table 1). Nearly two-thirds of the cases of drug-
induced TdP occur in women. Clinical and experimental 
studies show that female gender is associated with a longer 
corrected QT interval at baseline and a greater response to 
drugs that prolong the QT interval. Even in the presence of a 
drug that mildly blocks IKr and seldom or mildly prolongs 
the QT interval, women are still more prone to drug-induced 
TdP [5, 95]. Further, genetic defects of K
+ channels that may 
be asymptomatic in normal conditions may precipitate drug-
induced arrhythmia in women more frequently than in men. 
It has been proposed that women have a reduced cardiac 
'repolarisation reserve' possibly due to an effect of estrogens. 
In fact, estrogens are known to facilitate bradycardia-induced 
prolongation of the QT interval and emergence of 
arrhythmia, whereas androgens shorten the QT interval and 
blunt the QT response to drugs [95].  
  Amiodarone, bepridil, quinidine, disopyramide, ibutilide, 
sotalol, erythromycin, pimozide, probucol, cisapride, terfena-
dine and halofantrin are among the drugs reported to increase 
risk of TdP in women [15, 95, 96]. 
  Prolonged QT in the elderly is strongly associated with 
the development of ventricular arrhythmias [97]. As pre-
viously described, in addition to gender and older age, 
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systolic dysfunction, HIV, hypokalemia and hypoma-
gnesemia are well-known risk factors for drug-induced TdP. 
Coexistence of several of these factors in an individual 
increases the risk of drug-induced TdP (Table 1).  
  A previous history of drug-induced TdP predicts 
excessive QT prolongation when exposed to a QT-pro-
longing drug [52] (Table 1). The QT prolonging effects of D, 
L-sotalol (2mg/kg, i.v.) were assessed in subjects with a 
history of TdP in association with QT-prolonging drug use 
and in age and sex matched controls. Although there were no 
differences in baseline QTc intervals between groups, sotalol 
increased QTc interval duration from 422+/-17 to 450+/-
22ms in controls, and from 434+/-20 to 541+/-37ms in study 
subjects. TdP occurred in 3 of 20 in the study population but 
in none of the controls [52]. Assuming no differences in 
sotalol pharmacokinetics among groups, the findings suggest 
that subjects with a history of drug-induced TdP despite 
normal QTc at baseline have subclinical repolarization 
defects that were unmasked by sotalol. The findings also 
indicate that a normal QTc at baseline does not preclude 
excessive QT prolongation, nor development of TdP when 
exposed to a QT-prolonging drug [52]. Therefore, a previous 
history of drug-induced TdP, even in the presence of a 
normal QTc interval duration, should preclude further use of 
QT prolonging drugs. It is quite possible that subclinical ion 
channel mutations may account for the increased risk of QT 
lengthening and TdP observed in many individuals. 
  The presence of repolarization inhomogeneity assessed 
through measurements of QT dispersion has also been 
proposed as a predictor for drug-induced TdP. Chevalier and 
colleagues reported greater QT dispersion in subjects with a 
history of drug-induced transient QT lengthening >600 ms 
and/or TdP than in controls [98].  
  To determine whether relatives of subjects with a history 
of long QT are at increased risk for QT prolongation, 
intravenous quinidine was given to relatives of subjects who 
developed long QT after administration of QT-prolonging 
drugs and to relatives of subjects who failed to prolong the 
QTc interval (controls) [99]. No differences in QT between 
groups were observed at baseline or after quinidine. 
However, the interval from the peak to the end of the T 
wave, an index of transmural dispersion of repolarization, 
prolonged significantly with quinidine in first-degree 
relatives of patients who prolonged the QT interval, but not 
in control relatives. Although the study was conducted in a 
small number of subjects, the findings suggest the existence 
of a genetic predisposition to acquired (drug-induced) long 
QT [99] (Table 1). To what extent the observed T wave 
abnormality indicates increased risk for developing TdP 
deserves further work.  
PRACTICAL ASPECTS 
  The following information should be collected prior to 
administer a QT-prolonging drug in order to prevent or 
minimize risk of drug-induced TdP:  
1. Past Medical History. Rule out congenital long QT 
syndrome, history of arrhythmia and/or syncope 
either spontaneous or associated with drug use, 
presence of ischemic heart disease, cardiomyopathy   
and/or systolic dysfunction-heart failure, or HIV. 
Relatives of subjects with history of congential or 
acquired TdP or drug-induced long QT may also be at 
increased risk.  
2. Medication history. Determine drug-use associated 
with previous arrhythmia/syncope or long QT. A 
previous history of drug-induced TdP should preclude 
the use of a QT prolonging drug. On current medi-
cation list, check for QT-prolonging drugs used alone 
or combined with inhibitors of drug-metabolism. Use 
of two or more drugs known to prolong the QT 
should be avoided. Beta-receptor agonists and sym-
pathomimetics should also be avoided in subjects 
with increased risk.  
3. Identify additional risk factors and combination of 
risk factors. Women are at greater risk of TdP than 
men. Elderly women on antipsychotic or anti-
depressant medication, needing antiarrhythmic and/or 
antibiotic treatment must be carefully monitored. 
Avoid high doses of QT prolonging drugs.  
4. Baseline ECG. Examine for heart rate 
(bradycardia), QTc duration and dispersion, presence 
of T wave abnormalities, U waves, and T wave 
alternants. QTc values greater than 450 msec for men 
and greater than 470 msec for females are usually 
considered as abnormally prolonged. Estimate QT 
dispersion using the difference between the maximum 
and the minimum QTc in any thoracic lead. Values 
greater than 80 msec are considered abnormally 
prolonged. When prolonged QT is associated with 
increased QT dispersion use of drugs that may further 
prolong the QT interval must be avoided, since such a 
combi-nation is known to increase the risk for 
developing drug-induced TdP [98]. 
5. Obtain serum K
+, magnesium and creatinine levels 
before starting treatment with a QT-prolonging drug. 
Normalize serum K
+ and magnesium if low. Assure 
normal renal function when administering QT pro-
longing drugs that are mainly eliminated by the 
kidney.  
6. Treatment and follow-up plan. Avoid high doses of 
QT prolonging drugs and combinations of drugs 
known to prolong the QT interval. If a QT prolonging 
drug must be used, use it at low doses and avoid high 
peak levels and intravenous administration. Monitor 
QT on ECG during treatment. Avoid combined use of 
long QT drugs with drugs that inhibit their meta-
bolism and may induce accumulation and high 
plasma levels.  
7. Incorporate genetic testing in high-risk populations 
(family history, previous multiple syncopal episodes, 
previously documented TdP arrhythmia), as well as 
provocation tests (i.e, epinephrine QT test) [100]. 
Epinephrine QT stress testing is an effective diag-
nostic tool to unmask concealed long QT syndrome. 
Better understanding of HERG channel function and 
regulation is needed to diagnose and treat cardiac 
repolarization disorders and the development of 
severe and potentially fatal arrhythmias.  174 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Luigi X. Cubeddu
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